Apellis Pharmaceuticals is a biotechnology business based in the US. Apellis Pharmaceuticals shares (APLS) are listed on the NASDAQ and all prices are listed in US Dollars. Apellis Pharmaceuticals employs 476 staff and has a trailing 12-month revenue of around $113 million.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $52.77 |
|---|---|
| 52-week range | $33.32 - $70.00 |
| 50-day moving average | $49.71 |
| 200-day moving average | $52.43 |
| Wall St. target price | $74.88 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-7.87 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $52.77 from 2023-01-27
| 1 week (2023-01-23) | 4.27% |
|---|---|
| 1 month (2022-12-30) | 2.05% |
| 3 months (2022-10-28) | -12.92% |
| 6 months (2022-07-29) | -6.24% |
| 1 year (2022-01-28) | 36.75% |
|---|---|
| 2 years (2021-01-29) | 19.20% |
| 3 years (2020-01-30) | 27.13% |
| 5 years (2018-01-30) | 188.83% |
| Revenue TTM | $113 million |
|---|---|
| Gross profit TTM | $-253,920,000 |
| Return on assets TTM | -46.47% |
| Return on equity TTM | -507.11% |
| Profit margin | 0% |
| Book value | $2.78 |
| Market capitalisation | $5.7 billion |
TTM: trailing 12 months
We're not expecting Apellis Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Apellis Pharmaceuticals's shares have ranged in value from as little as $33.32 up to $70. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Apellis Pharmaceuticals's is 1.2264. This would suggest that Apellis Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Apellis Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.